Zoledronate In the Prevention of Paget's Disease: Long Term Extension (ZiPP-LTE)

Paget's disease of the bone (PDB) is a metabolic bone disorder which in some individuals can cause pain, bone deformity, arthritis and deafness, although in many patients it does not cause symptoms. Paget's disease has a strong genetic component and SQSTM1 is the most important susceptibility gene. People who inherit mutations in SQSTM1 have a high risk of developing PDB later in life. This study is an extension of the ZiPP (Zoledronate in the Prevention of Paget's) study which was is randomised trial currently in progress to determine if the bisphosphonate zoledronic acid (ZA) can prevent or delay the development of PDB-like bone lesions compared with a dummy treatment (placebo) in people who inherit SQSMT1 gene mutations. Although the ZiPP study will provide information on whether early ZA treatment can favourably influence bone lesion development the significance of this to the patient in terms of symptoms is unclear as yet. The aim of the extension study is to keep these individuals under surveillance for any symptoms or signs of PDB over a further 5 year period and to evaluate if there has been any progression of PDB-like lesions by bone scan at the end of this period.

Study Overview

• Status: Enrolling by invitation
• Conditions: Paget Disease

Detailed Description

It is at present unclear whether intervention with bisphosphonates is of clinical benefit in early PDB. Although the ZiPP study is expected to provide information on whether ZA can favourably influence the development of bone lesions characteristic of early PDB as determined by radionuclide bone scan imaging, longer term follow up is required to determine if this will translate into clinical benefit. The extension study described here will provide new information on the natural history of PDB by follow up of people that took part in the ZIPP trial. Although the ZIPP-LTE study is an observational study, treatment for PDB may be given to participants according to normal clinical practice if they develop signs or symptoms of PDB during the extension. Treatment will therefore be offered to all participants that develop symptoms of PDB during follow up. Additionally, subjects that were previously been exposed to ZA in the core study will also be offered further ZA or another bisphosphonate licensed for PDB if they develop evidence of increased metabolic activity thought to be due to PDB, even if asymptomatic. The reason for this is that adverse effects are rare in patients who have previously been treated with ZA but are common on first exposure to ZA. Both therapeutic approaches are commonly used in patients with early PDB with no evidence that one is superior to another. In addition to providing information on the natural history of PDB, part of the aim of the extension will be to evaluate the risks and benefits of these two approaches to standard care of in terms of new lesion development, pain, quality of life and adverse events in the context of people who inherit SQSTM1 mutations.

• Study Type: Observational
• Enrollment (Estimated): 287

Contacts and Locations

• Study Contact: Name: Jonathan Phillips, PhD; Phone Number: 07773309603; Email: ZIPP-LTE@ed.ac.uk
• Study Contact Backup: Name: Berg Kathryn; Email: ZIPP-LTE@ed.ac.uk

Study Locations

• Australia
  • Geelong, Australia, 3220
    • University Hospital Geelong
  • Nedlands, Australia, 6009
    • Sir Charles Gardner Hospital
  • Newcastle, Australia, NSW 2305
    • Royal Newcastle Centre
  • Sydney, Australia
    • University of Sydney
  • Toowoomba, Australia, QLD 4350
    • University of Queensland
• Belgium
  • Brussels, Belgium
    • University Hospital Saint-Luc
• Ireland
  • Dublin, Ireland
    • St. Vincent's University Hospital
• Italy
  • Florence, Italy, 50139
    • University Hospital of Careggi
  • Siena, Italy, 53100
    • University of Siena
  • Turin, Italy, 10126
    • University of Turin
• New Zealand
  • Auckland, New Zealand, 92019
    • University of Auckland
  • Christchurch, New Zealand, 731 8022
    • The Princess Margaret Hospital
• Spain
  • Barcelona, Spain
    • Univeristy of Barcelona
  • Salamanca, Spain, 37007
    • University Hospital of Salamanca
• United Kingdom
  • England
    • Bristol, England, United Kingdom, BC10 5NB
      • University of Bristol
    • Liverpool, England, United Kingdom, L7 8XP
      • University of Liverpool
    • London, England, United Kingdom, SE5 9RS
      • King's College Hospital
    • London, England, United Kingdom, SE1 9RT
      • Guy's and St Thomas Hospital NHS Trust
    • Manchester, England, United Kingdom, M13 9WL
      • Manchester Royal Infirmary
  • Scotland
    • Edinburgh, Scotland, United Kingdom, EH4 2XU
      • NHS Lothian
  • Wales
    • Wrexham, Wales, United Kingdom, LL13 7TD
      • Wrexham Maelor Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients recruited to the ZiPP Trial (2008-005667-34)

Description

Inclusion Criteria:

• Subject that participated in ZiPP
• Participant willing and able to consent and comply with the study protocol.

Exclusion Criteria:

• Unable or unwilling to provide informed consent

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Observational (without bone scan); Former Observational Arm participants of the ZiPP trial.
Observational (with bone scan); Former Interventional Arm participants of the ZiPP trial.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Endpoint (former ZiPP interventional arm): The proportion of patients that develop PDB-like bone lesions	The proportion of patients in each of the randomisation groups that develop PDB-like bone lesions by the end of study assessed by radionuclide bone scan.	5 year time-point
Primary Endpoint (former ZiPP observational arm): proportion of individuals that develop abnormalities suggestive of PDB	The primary endpoint will be to evaluate the proportion of individuals that develop biochemical or clinical abnormalities suggestive of PDB over a the 10-year duration of follow up.	During follow-up period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary Endpoint (former ZiPP interventional arm): Differences between ZiPP trial treatment and placebo groups with regard to the number of new bone lesions assessed by radionuclide bone scan.		5 year time-point
Secondary Endpoint (former ZiPP interventional arm): Evaluate differences between ZiPP treatment and placebo groups for change in bone lesion activity by semi-quantitative analysis of radionuclide bone scans (method described by Patel et al (1995)).		5 year time-point
Secondary Endpoint (former ZiPP interventional arm): Differences between ZiPP trial treatment and placebo groups with regard to SF36 (36-Item Short Form Survey) scores.		5 year time-point
Secondary Endpoint (former ZiPP interventional arm): Differences between ZiPP trial treatment and placebo groups with regard to HAQ (Health Assessment Questionnaire) scores.		5 year time-point
Secondary Endpoint (former ZiPP interventional arm): Differences between ZiPP trial treatment and placebo groups with regard to EQ5D (EuroQol five dimension scale) scores.		5 year time-point
Secondary Endpoint (former ZiPP interventional arm): Differences between ZiPP trial treatment and placebo groups with regard to IPAQ (International Physical Activity Questionnaire) scores.		5 year time-point
Secondary Endpoint (former ZiPP interventional arm): Differences between ZiPP trial treatment and placebo groups with regard to BPI (Brief Pain Inventory Scale) scores.		5 year time-point
Secondary Endpoint (former ZiPP interventional arm): Differences between ZiPP trial treatment and placebo groups with regard to development of PDB-related skeletal events (PRSE).	Defined as new bone lesions thought to be due to PDB on imaging OR complications of PDB such as pathological fractures, bone deformity, deafness, and joint replacement surgery OR administration of treatment for PDB because of pain localised to an affected site in a patient with metabolically active disease.	5 year time-point
Secondary Endpoint (former ZiPP observational arm): Health-related quality of life in ZiPP trial observational arm participants assessed using EQ5D.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Health-related quality of life in ZiPP trial observational arm participants assessed using SF36.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Health-related quality of life in ZiPP trial observational arm participants assessed using BPI.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Health-related quality of life in ZiPP trial observational arm participants assessed using HAQ.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Health-related quality of life in ZiPP trial observational arm participants assessed using IPAQ.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Pain in ZiPP trial observational arm participants assessed using EQ5D.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Pain in ZiPP trial observational arm participants assessed using SF36.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Pain in ZiPP trial observational arm participants assessed using BPI.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Anxiety in ZiPP trial observational arm participants assessed using EQ5D.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Anxiety in ZiPP trial observational arm participants assessed using SF36.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Depression in ZiPP trial observational arm participants assessed using SF-36.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Depression in ZiPP trial observational arm participants assessed using BPI.		5 year time-point
Secondary Endpoint (former ZiPP observational arm): Depression in ZiPP trial observational arm participants assessed using EQ5D.		5 year time-point

Collaborators and Investigators

• Sponsor: University of Edinburgh
• Collaborators: European Research Council
• Investigators: Principal Investigator: Stuart Ralston, Prof, Univeristy of Edinburgh

Study record dates

Study Major Dates

• Study Start (Actual): April 5, 2019
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: January 31, 2019
• First Submitted That Met QC Criteria: February 28, 2019
• First Posted (Actual): March 1, 2019

Study Record Updates

• Last Update Posted (Actual): November 29, 2023
• Last Update Submitted That Met QC Criteria: November 28, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: AC18051; 245197 (Other Identifier: IRAS (Integrated Research Application System)); 18/ES/0086 (Other Identifier: Research Ethics Committee (EoSRES))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No